ROIV 株価分析 — Roivant Sciences LTD (Healthcare >> Biotechnology)
ROIV に関するよくある質問
ROIVのPER(株価収益率)は?
Roivant Sciences LTD(ROIV)は現在PER 90.91倍で取引されています。
ROIVのROE(自己資本利益率)は?
Roivant Sciences LTDのROEは-6.62%です。
ROIVの配当利回りは?
Roivant Sciences LTDの配当利回りは0.00%です。
ROIVの品質スコア(Quality Score)は?
当社のAIはROIVの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ROIVは今が買い時ですか?
当社AIのタイミングスコアは100点中66点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ROIVはどのセクターに属しますか?
Roivant Sciences LTDはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
ROIV AI Analysis Summary
Our AI summary for ROIV: Roivant Sciences LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 90.91, ROE of -6.62%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 33.91
Price
-0.61
(-1.77%)
Day Change
|
|
|---|
ROIV, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 33.91 |
| PBV / Sector |
5.20 / 5.20
|
| Earning Per Share | -0.43 |
| PE / Sector |
90.91 / 19.97
|
| PEG or PE/Growth / Sector |
-0.32 / 1.22
|
| Average 1M Daily Value |
153.45 M
GREAT
|
| Average 1W Daily Value |
154.12 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:25 |
| Symbol | ROIV |
| Name | ROIVANT SCIENCES LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 722.41 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 27,544.66 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 50 Broadway, London, United Kingdom, SW1H 0DB
Phone: 44 20 7400 3347
Website: https://roivant.com
Employees: 721
Sector: Healthcare >> Biotechnology
Description: Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google